Proportional hazards model

Clinical trial

Environmental health

Coronavirus disease 2019 (COVID-19)

Placebo

Alternative medicine

Population

Infectious disease (medical specialty)

Internal medicine

Medicine

Pandemic

Disease

Pathology

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Vital capacity (VC) is routinely used for ALS clinical trial eligibility determinations, often to exclude patients unlikely to survive trial duration. However, spirometry has been limited by the COVID-19 pandemic. We developed a machine-learning survival model without the use of baseline VC and asked whether it could stratify clinical trial participants and a wider ALS clinic population.

Development and validation of a machine-learning ALS survival model lacking vital capacity (VC-Free) for use in clinical trials during the COVID-19 pandemic